Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMR PH GL 2007 CL 001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Next Previous
Trial Profile

AMR PH GL 2007 CL 001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amrubicin (Primary) ; Topotecan
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ACT-1
  • Sponsors Celgene Corporation; Pharmion Corporation

Most Recent Events

  • 23 Jun 2012 Company added in the association field as reported by EudraCT.
  • 08 Nov 2011 Results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
  • 07 Jul 2011 Results reporting symptom control and quality of life presented at the 14th World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top